4CPS-166 Implementation of a linezolid pharmacokinetic monitoring programme
Background and ImportanceLinezolid is an antibiotic that presents high inter- and intra-individual variability and therefore may compromise its clinical efficacy or increase the risk of associated toxicity.Aim and ObjectivesTo establish a programme for monitoring linezolid plasma levels that will al...
Saved in:
Published in | European journal of hospital pharmacy. Science and practice Vol. 30; no. Suppl 1; p. A77 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
British Medical Journal Publishing Group
23.03.2023
BMJ Publishing Group LTD |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background and ImportanceLinezolid is an antibiotic that presents high inter- and intra-individual variability and therefore may compromise its clinical efficacy or increase the risk of associated toxicity.Aim and ObjectivesTo establish a programme for monitoring linezolid plasma levels that will allow us to proactively identify patients who can benefit most from its use and to evaluate its results in our centre.Material and MethodsA literature review was performed to define the criteria that allowed us to identify patients who were candidates for pharmacokinetic monitoring of linezolid.We established the determination of plasma concentrations before the administration of the 5th dose and then periodically every 3-4 days until the end of treatment. The efficacy and safety criterion was to maintain the trough plasma concentration (Cmin) in the therapeutic range (between 2 and 8 mg/L).ResultsThe criteria selected for the identification of patients who were candidates to be part of the monitoring programme were: critical patients, transplanted patients, severe burns or cystic fibrosis, obese patients (BMI > 30), kidney failure (creatinine clearance < 30 ml/min) and liver failure (Child Pugh C), renal replacement therapies, prolonged treatments (> 3 weeks) and treatment with Glycoprotein-P inducers.From January to April 2022, a total of 20 patients that met at least one of the aforementioned criteria were included in the programme . All patients started treatment in critical care units and the chosen route of administration was intravenous. Eighty-five percent of the patients were men, the median age was 69 years and the mean duration of treatment was 11.6 days.A total of 50 samples were analysed (2.5 samples per patient). The mean Cmin was 5.3 mg/L. Thirty samples (60%) were out of therapeutic range.Fifty pharmacokinetic reports were performed. In 60% of the cases, modifications of the dosing regimen were made: 17 were dose increases and 13 were dose decreases.Conclusion and RelevanceIncorporating this programme into clinical practice allows us to proactively identify the patients who could benefit most from linezolid monitoring.The results demonstrate the high variability of linezolid plasma levels and the usefulness of dosing recommendations issued by the Pharmacy service to ensure that the Cmin remains within the therapeutic range.References and/or AcknowledgementsConflict of InterestNo conflict of interest |
---|---|
AbstractList | Background and ImportanceLinezolid is an antibiotic that presents high inter- and intra-individual variability and therefore may compromise its clinical efficacy or increase the risk of associated toxicity.Aim and ObjectivesTo establish a programme for monitoring linezolid plasma levels that will allow us to proactively identify patients who can benefit most from its use and to evaluate its results in our centre.Material and MethodsA literature review was performed to define the criteria that allowed us to identify patients who were candidates for pharmacokinetic monitoring of linezolid.We established the determination of plasma concentrations before the administration of the 5th dose and then periodically every 3-4 days until the end of treatment. The efficacy and safety criterion was to maintain the trough plasma concentration (Cmin) in the therapeutic range (between 2 and 8 mg/L).ResultsThe criteria selected for the identification of patients who were candidates to be part of the monitoring programme were: critical patients, transplanted patients, severe burns or cystic fibrosis, obese patients (BMI > 30), kidney failure (creatinine clearance < 30 ml/min) and liver failure (Child Pugh C), renal replacement therapies, prolonged treatments (> 3 weeks) and treatment with Glycoprotein-P inducers.From January to April 2022, a total of 20 patients that met at least one of the aforementioned criteria were included in the programme . All patients started treatment in critical care units and the chosen route of administration was intravenous. Eighty-five percent of the patients were men, the median age was 69 years and the mean duration of treatment was 11.6 days.A total of 50 samples were analysed (2.5 samples per patient). The mean Cmin was 5.3 mg/L. Thirty samples (60%) were out of therapeutic range.Fifty pharmacokinetic reports were performed. In 60% of the cases, modifications of the dosing regimen were made: 17 were dose increases and 13 were dose decreases.Conclusion and RelevanceIncorporating this programme into clinical practice allows us to proactively identify the patients who could benefit most from linezolid monitoring.The results demonstrate the high variability of linezolid plasma levels and the usefulness of dosing recommendations issued by the Pharmacy service to ensure that the Cmin remains within the therapeutic range.References and/or AcknowledgementsConflict of InterestNo conflict of interest |
Author | Suárez Santamaria, M Prado Montes, P Couñago Fernández, M Lago Rivero, N Agra Blanco, I Robles Torres, D Campelo Sánchez, E Alfonsín Lara, M Martínez López de Castro, N |
Author_xml | – sequence: 1 givenname: D surname: Robles Torres fullname: Robles Torres, D organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain – sequence: 2 givenname: E surname: Campelo Sánchez fullname: Campelo Sánchez, E organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain – sequence: 3 givenname: N surname: Lago Rivero fullname: Lago Rivero, N organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain – sequence: 4 givenname: M surname: Suárez Santamaria fullname: Suárez Santamaria, M organization: ALVARO Cunqueiro Hospital, Clinical Analysis, Vigo, Spain – sequence: 5 givenname: M surname: Alfonsín Lara fullname: Alfonsín Lara, M organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain – sequence: 6 givenname: P surname: Prado Montes fullname: Prado Montes, P organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain – sequence: 7 givenname: M surname: Couñago Fernández fullname: Couñago Fernández, M organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain – sequence: 8 givenname: I surname: Agra Blanco fullname: Agra Blanco, I organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain – sequence: 9 givenname: N surname: Martínez López de Castro fullname: Martínez López de Castro, N organization: ALVARO Cunqueiro Hospital, Hospital Pharmacy, Vigo, Spain |
BookMark | eNpFkMtOwzAQAC1UJErpL6BInFP8imMfUQW0UhFI9G6tE6d1ie2QpBdOXPhRvoSU8jjtajXakeYcjUIMFqFLgmeEMHFtd9tmC61PKaYstbBtZkTQEzSmmOepUoKP_vZMnKFp1zmDM8ak4kyN0QOfPz2nRIjP94-lb2rrbeihdzEksUogqV2wb7F2ZfKtgSK-DJfeFYmPwfWxdWGTNG3ctOC9vUCnFdSdnf7MCVrf3a7ni3T1eL-c36xSQ4iiaYlzkCw3paIGJEiRFRgYA84LKUwliVGGYK4qnGVWSUZyxsHkSgIpq9KwCbo6vh3Er3vb9XoX920YjJrmChOOecYHih4p43f_AMH6EE7_htOHcPoQTg_h2BcI5Gcv |
ContentType | Journal Article |
Copyright | European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ. 2023 European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ. |
Copyright_xml | – notice: European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2023 European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ. |
DBID | K9. |
DOI | 10.1136/ejhpharm-2023-eahp.162 |
DatabaseName | ProQuest Health & Medical Complete (Alumni) |
DatabaseTitle | ProQuest Health & Medical Complete (Alumni) |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2047-9964 |
EndPage | A77 |
ExternalDocumentID | ejhpharm |
GroupedDBID | 0R~ 53G 7X7 8FI 8FJ AAYAA ABKRM ABUWG ABVAJ ABWEH ADBBV ADMRH AFKRA AHMBA AHQMW AJYBZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BENPR BPHCQ BTHHO C45 CCPQU CXRWF EBS FYUFA H13 HAJ HMCUK HYE OK1 OVD PQQKQ PROAC RHI RMJ RPM TEORI UKHRP K9. |
ID | FETCH-LOGICAL-b1192-d07a837bd92ba8a865c0a33a44c86bf81b9b1049f055e9831734ab798a1dfdb3 |
ISSN | 2047-9956 |
IngestDate | Thu Oct 10 22:07:10 EDT 2024 Tue Nov 26 16:39:27 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Suppl 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b1192-d07a837bd92ba8a865c0a33a44c86bf81b9b1049f055e9831734ab798a1dfdb3 |
Notes | 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023 |
OpenAccessLink | https://ejhp.bmj.com/content/ejhpharm/30/Suppl_1/A77.1.full.pdf |
PQID | 2790140454 |
PQPubID | 2040966 |
ParticipantIDs | proquest_journals_2790140454 bmj_journals_10_1136_ejhpharm_2023_eahp_162 |
PublicationCentury | 2000 |
PublicationDate | 20230323 |
PublicationDateYYYYMMDD | 2023-03-23 |
PublicationDate_xml | – month: 3 year: 2023 text: 20230323 day: 23 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | European journal of hospital pharmacy. Science and practice |
PublicationTitleAbbrev | Eur J Hosp Pharm |
PublicationYear | 2023 |
Publisher | British Medical Journal Publishing Group BMJ Publishing Group LTD |
Publisher_xml | – name: British Medical Journal Publishing Group – name: BMJ Publishing Group LTD |
SSID | ssib053389439 ssj0000605265 ssib018287486 |
Score | 2.2853594 |
Snippet | Background and ImportanceLinezolid is an antibiotic that presents high inter- and intra-individual variability and therefore may compromise its clinical... |
SourceID | proquest bmj |
SourceType | Aggregation Database Publisher |
StartPage | A77 |
SubjectTerms | Conflicts of interest Pharmacokinetics Plasma Section 4: Clinical pharmacy services |
Title | 4CPS-166 Implementation of a linezolid pharmacokinetic monitoring programme |
URI | https://ejhp.bmj.com/content/30/Suppl_1/A77.1.full https://www.proquest.com/docview/2790140454 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07b9swECacZOlStGiLpk0NDd0EuZL5kDimQYqgaIIgdgFvAknRcFNbChx7qKcu_aPd-i96fEiyEg9JFsEmREK6O5Efj3ffIfRRqFRxXbAIsHUWEZrCPEg4jgRnSgE8oVTYANkLdvadfJ3QSa_3bytqab2SA7XZmVfyFK1CG-jVZMk-QrPNoNAAv0G_cAUNw_VBOiYnl6MoYcxHLGTUcv0ufDpR6XIfDY7cVPMfRXjjaap_QovhaV3Y73np8tFtmFaXuaDjqfeodebrjNSD_Ro004OjHHBJV-05jpzr23Bsa4B0AozNoYeeV-HIHtUnJRjPppMZ8c1EiFyZsJGqe2S0dj2WehOOwC7EArb7onXsehfGEJsYLpdl7Px0nr6pPpqqofhOR5ydGoeGX8Lk5LpVbLvNcaLXc7s_83E2bOukhsnWdH3sS8jo7X_3FxVX9eZ6ZiUb2TfQYnYzSPxC0mHxNvd1Wy1aqLvvoQPD2Ui6jqXE1h1omfwAhBtifN64C2NmiHlMQG7z7j7fHZ7u0-5nA7gkF9f3QIZFTuMX6LmXc3Ds7Pcl6unyFTqvbffv7z9dqw2qaSCCxmqDO1YbtFYbNFb7Go2_nI5PziJf2iOSCewpoiJORYZTWfChFJnIGFWxwFgQojImp7CX4jKBzesUJgvNMwC5mAiZ8kwkxbSQ-A3aL6tSv0VBzCRXmhVxMcSExoqnFEC8JpRgU7ygOEQhCCH3H8ptbje9mOW1yHIjstyILAeRHaKjWlhtF9CXZaGi5N2jBnuPnrXWfoT2V8u1_gAQdiX7aC-dpH108Pn04vKqb03hP4uJoAs |
link.rule.ids | 314,780,784,27924,27925,31719,33744 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=4CPS-166%E2%80%85Implementation+of+a+linezolid+pharmacokinetic+monitoring+programme&rft.jtitle=European+journal+of+hospital+pharmacy.+Science+and+practice&rft.au=Robles+Torres%2C+D&rft.au=Campelo+S%C3%A1nchez%2C+E&rft.au=Lago+Rivero%2C+N&rft.au=Su%C3%A1rez+Santamaria%2C+M&rft.date=2023-03-23&rft.pub=British+Medical+Journal+Publishing+Group&rft.issn=2047-9956&rft.eissn=2047-9964&rft.volume=30&rft.issue=Suppl+1&rft.spage=A77&rft.epage=A77&rft_id=info:doi/10.1136%2Fejhpharm-2023-eahp.162&rft.externalDBID=ejhp&rft.externalDocID=ejhpharm |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9956&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9956&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9956&client=summon |